Disease details

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

5 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01910259 (ClinicalTrials.gov)	December 18, 2014	19/7/2013	MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial	A Multi-arm Phase IIB Randomised, Double Blind Placebo-controlled Clinical Trial Comparing the Efficacy of Three Neuroprotective Drugs in Secondary Progressive Multiple Sclerosis.	Secondary Progressive Multiple Sclerosis	Drug: Amiloride;Drug: Riluzole;Drug: Fluoxetine;Drug: Placebo	University College, London	Medical Research Council;National Institute for Health Research, United Kingdom;MS Society;University of Edinburgh;Queen Mary University of London;Keele University;University of Sheffield;University of Leeds;University of Warwick	Completed	25 Years	65 Years	All	445	Phase 2	United Kingdom
2	EUCTR2012-005394-31-GB (EUCTR)	01/04/2014	05/09/2014	MS-SMART: A Trial of Efficacy (usefulness) of 3 Neuroprotective Drugs in SPMS	MS-SMART: A Multi-Arm Phase IIb Randomised, Double Blind Placebo-Controlled Clinical Trial Comparing The Efficacy of Three Neuroprotective Drugs in Secondary Progressive Multiple Sclerosis - MS-SMART: Multiple Sclerosis Secondary Progressive Multi-Arm Randomisation Trial	Mutliple Sclerosis (Secondary Progressive);Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Rilutek Product Name: Rilutek INN or Proposed INN: Riluzole Trade Name: Amiloride Product Name: Amiloride INN or Proposed INN: Amiloride Trade Name: Fluoxetine Product Name: Fluoxetine INN or Proposed INN: Fluoxetine hydrochloride	UCL	NULL	Not Recruiting			Female: yes Male: yes	440	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no	United Kingdom
3	EUCTR2012-005113-39-AT (EUCTR)	08/04/2013	18/02/2013	Amiloride Hydrochlorothiazide as Treatment of Acute Inflammation of the Optic Nerve.	A Randomized, Placebo-Controlled, Double-Blind, Phase IIa Study of Amiloride in the Treatment of Acute Autoimmune Optic Neuritis - Amiloride Hydrochlorothiazide in acute autoimmune optic neuritis	Optic neuritis is among the most common first symptoms of multiple sclerosis leading to significant atrophy of the optic nerve within a short period of time, thus reflecting neurodegneration.;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Amilostad HCT Product Name: Amilostad HCT tablets INN or Proposed INN: AMILORIDE HYDROCHLORIDE , 2 H2O Other descriptive name: Amiloride Hydrochloride INN or Proposed INN: hydrochlorothiazide Other descriptive name: HYDROCHLOROTHIAZIDE	Universitätsklinik für Neurologie, Medizinische Universität Wien	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes		Phase 2	Austria
4	NCT01802489 (ClinicalTrials.gov)	February 2013	27/2/2013	Amiloride Clinical Trial In Optic Neuritis	A Double Blind Randomised Control Trial on Neuroprotection of Amiloride in Optic Neuritis	Optic Neuritis;Multiple Sclerosis	Drug: Amiloride;Drug: Placebo	University of Oxford	Multiple Sclerosis Society of Great Britain and Northern Ireland	Completed	18 Years	55 Years	All	46	Phase 2	United Kingdom
5	EUCTR2007-004051-11-GB (EUCTR)	18/12/2008	15/07/2008	Amiloride Treatment in Multiple Sclerosis - Amiloride in MS	Amiloride Treatment in Multiple Sclerosis - Amiloride in MS	Multiple Sclerosis	Trade Name: Amiloride Product Name: Amiloride Hydrochloride	Oxford Racliffe NHS Trust	NULL	Not Recruiting			Female: yes Male: yes	23		United Kingdom

先頭へ